Catalyst Pharmaceuticals (STU:CN2) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CN2 Catalyst Pharmaceuticals Inc STU:CN2
70 GF Score
Price €27.50
GF Value €21.84
! 6 Warning Signs
View Full Analysis

What is Catalyst Pharmaceuticals Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:CN2
70GF Score
Catalyst Pharmaceuticals Inc STU:CN2
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Catalyst Pharmaceuticals (STU:CN2) Overvalued in 2026?

Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued. The current stock price of €27.50 is trading 25.9% above its estimated GF Value™ of €21.84.

Key valuation signals for STU:CN2:

  • Dividends Received:
  • GF Value™: €21.84 vs. price of €27.50 (25.9% above fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the STU:CN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Catalyst Pharmaceuticals Business Description

Other Exchanges CPRX:USA
Address 355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
70GF Score

Get the complete analysis for STU:CN2

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.50
Price
€21.84
GF Value